logo
Where Did Bird Flu Go?

Where Did Bird Flu Go?

For months, bird flu was seemingly everywhere in the U.S.: news headlines reported the highly pathogenic H5N1 avian influenza virus was rapidly sweeping through hundreds of herds of dairy cattle and leading to massive culls of poultry flocks, concerning infections in humans and grocery store aisles where nary an egg could be found.
But nearly as quickly as bird flu took hold in daily conversations, it disappeared from them and most people's thoughts—making it easy for the public to think avian influenza's threat had waned. Far from it, experts say. 'The flu is still there, and we just don't know enough about it,' says Angela Rasmussen, a virologist at the University of Saskatchewan.
What made the virus apparently fade away—and what does that mean for the future of bird flu?
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
One scenario experts have definitively ruled out is that the currently circulating bird flu virus—a member of a subtype of influenza called H5N1 for the proteins on its surface—is simply vanishing on its own, says Jennifer Nuzzo, an epidemiologist at Brown University. 'There has been this wishful thinking that it's just going to wipe through and be gone, and we've just not seen that, and that's just not how flu viruses work,' Nuzzo says. 'This isn't going away.'
Experts are still monitoring for H5N1 avian influenza in a variety of animals: wild birds, commercial poultry animals, wild mammals, dairy cattle and humans—and finding it, albeit at lower rates. But the virus is tricky, behaving somewhat differently in each host. Here's what we know about the current state of the virus.
The most reliable data on bird flu prevalence come from poultry operations. That's because the virus is so devastating in chickens and turkeys that farmers must cull flocks as soon as they detect an infection to reduce spread. They are also able to report outbreaks to the federal government to receive partial compensation. There's no way to ignore a sick flock or any incentive to hide one.
And right now poultry tolls to avian influenza are relatively low. Farmers reported just three million poultry birds killed by the virus or culled to stop it in March and April combined compared with 23 million and 12 million in January and February, respectively. May saw more than five million birds dead after the virus infiltrated several massive egg-laying facilities in Maricopa County, Arizona. But June rates fell far below one million birds, and July cases to date remain very low, with just one commercial facility affected so far.
These lower rates of bird flu aren't particularly surprising, given the virus's past behavior in poultry to date, says Mike Persia, a poultry specialist at Virginia Tech. 'We generally see a reduction in infections over the summer,' he says. Since the current outbreak began in early 2022, U.S. Department of Agriculture data show that, each year, the monthly count of affected poultry birds has tended to dip to under five million in June, July and August.
Two factors seem to contribute to the apparent seasonal trend, Persia says. The virus appears to falter in higher ambient temperatures, and the migratory wild birds that typically introduce the virus into poultry flocks aren't traveling as widely now that breeding season is in full swing.
But the outbreak's history tells a cautionary tale: each autumn, the number of affected poultry birds rises again—so it would be premature to assume H5N1 is done with us. 'I'm optimistic that maybe this was the last of it, and it goes away forever. I wouldn't take the lull as proof of that, though,' says Jada Thompson, an agricultural economist at the University of Arkansas. 'We need to maintain vigilance.'
Evaluating the outbreak in U.S. dairy cattle has been more difficult. Cows that are sick with bird flu eat less and produce thick and discolored milk. But the infection isn't nearly as fatal in cattle as it is in poultry, making the virus harder to see in the former. And there's no recompense for lost milk to encourage farmers to report being hit.
In addition, the virus's jump into dairy cattle in late 2023 was wildly unexpected and not publicly confirmed until March 2024, giving dairy farmers and virologists little time to understand bird flu's tendencies in the species. Last year cases continued throughout the summer, particularly in the hard-hit state of Colorado. Spread proved to be difficult to contain, in part because of the movement of animals required by the dairy industry. And although the virus can be monitored through milk, officials only began mandating such testing last December, after a full year of viral circulation.
This year reported infections have trailed off, with only two herds confirmed to have the virus in all of June. But it's unclear how to interpret the trend—dairy farmers, too, are left poised between caution and optimism.
Throughout the outbreak, bird flu risk to humans has been low, although dairy and poultry workers with exposure to infected animals have been more vulnerable. The first detected human infection in 2024 came shortly after confirmation that dairy cattle had become sick with H5N1. Additional human cases came in flurries throughout the intervening months, totaling 70 confirmed infections, including one death, by mid-February. Since then, infection tallies at the Centers for Disease Control and Prevention have stalled.
Experts doubt that's a good thing. 'I can't rule out that part of why we're not finding infections is: we're just simply not looking for them,' Nuzzo says.
Throughout the outbreak, the CDC has kept a running tally of the testing it is conducting, and those numbers paint a clear picture. As of July 1, the CDC noted that more than 880 people had been subject to targeted testing after exposure to infected animals. On March 1 that number had been more than 840; in contrast, the February 1 number was more than 660. The CDC tested more than four times as many people in February as in March, April, May and June combined. Another way experts have kept tabs on bird flu has been through existing national flu surveillance—but because normal flu infections are in a seasonal lull, so are tests through that network.
The result is a lot of question marks. 'We are in sort of a perfect storm of no testing,' Rasmussen says.
Even wastewater monitoring, which has proven helpful in understanding levels of the virus that causes COVID as testing rates have fallen, is of limited help. The approach looks for the presence of viruses in community water processing plants, but H5N1 is spread so broadly across species that it is nearly impossible to use these detections to definitively trace sources.
'You don't know how it got there,' Nuzzo says of the virus in wastewater. 'You don't know if people are infected; you don't know if [the virus is present] because birds were hanging out in the wastewater.' In some cases, spikes in wastewater levels of H5N1 have even been linked to farmers dumping milk from their infected cows.
Nuzzo suspects that there have certainly been more human cases of avian influenza than the 70 confirmed to date but that the virus is not spreading widely. 'I don't think there's some huge iceberg of infections that we're missing,' Nuzzo says.
Nuzzo and Rasmussen find that cold comfort, however. Instead they emphasize how vital it is to have as much intel as possible about what H5N1 is doing. Choosing not to seek out evidence of the virus's behavior means passing up on the opportunity to catch any early signs of a pandemic in the making.
'No news in my world is not good news,' Rasmussen says. 'We're just not collecting any data, and those are two very, very different things.'
The U.S.'s current approach is simply further shrouding a situation that is already difficult to parse—given the complexity of a multispecies outbreak and the unpredictable nature of rapidly changing influenza viruses.
'This is the kind of thing that could become a pandemic tomorrow, [or] it could never become a pandemic. And I don't know which one is going to happen,' Rasmussen says.
'This is a huge risk, but it's also a risk that may never come to pass,' she says. 'But we won't know if we just stop looking for it.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Few will remember this earthquake, but something far worse is looming
Few will remember this earthquake, but something far worse is looming

Yahoo

time5 hours ago

  • Yahoo

Few will remember this earthquake, but something far worse is looming

The Kamchatka Peninsula earthquake may not have brought the same devastation as previous shocks, but a far more deadly seismic event is looming for the US West Coast. A major 600-mile-long fault line known as the Cascadia Subduction Zone runs from northern Vancouver Island in Canada to Cape Mendocino in northern California. Scientists have predicted there is a 15 per cent chance of a major earthquake there in the next 50 years, which could bring a mega-tsunami hundreds of feet high to US coastlines. A study from Virginia Tech in April showed an earthquake of force eight or above could cause coastal land to sink 6.5 feet within minutes, devastating cities such as Seattle and Portland and flooding hundreds of miles of roadway, airports, schools, hospitals and power plants. Researchers determined that the most severe effects would hit densely populated areas in northern California, southern Washington and northern Oregon. Like the Kamchatka quake, the Cascadia fault line lies in the 'Pacific Ring of Fire' – a 25,000-mile horseshoe of 452 volcanoes which stretches from the southern tip of South America, along the coast of North America, across the Bering Strait, Japan and New Zealand. The ring produces around 90 per cent of the world's earthquakes. Bill McGuire, the Professor Emeritus of Geophysical & Climate Hazards at University College London, said: 'Along with many active volcanoes, great earthquakes are a feature of the so-called Ring of Fire, each one releasing strain that has accumulated over centuries, as an over-riding tectonic plate snags on the one below, and eventually lets go.' Earthquakes only rarely cause mass devastation because they tend to occur away from major populations, he said, adding: 'Although locally destructive, tsunami heights at remote locations such as Hawaii and Japan seem modest, so widespread devastation and loss of life is unlikely.' The last great earthquake in the Cascadia subduction zone happened on Jan 26 1700, and geological evidence shows it caused dramatic land subsidence and drowned coastal marshes across the Pacific Northwest. Geologic evidence from the last six to seven thousand years indicates that 11 great earthquakes have happened approximately every 200 to 800 years, meaning 'the big one' may be imminent. 'This is not a distant or abstract threat,' said Tina Dura, the study's lead author and assistant professor in Virginia Tech's Department of Geosciences. 'The probability of a great earthquake is growing, and climate change is compounding the risks. We must factor these compound hazards into long-term planning now.' Earthquakes are now measured on the Moment Magnitude Scale, which is a modern development of the Richter scale, and records the amount of ground shaking and the amount of seismic energy released. The bigger the number, the worse it is. The biggest earthquake ever recorded was of magnitude 9.5 and occurred in Chile in 1960, at a fault line where the Pacific plate dives under the South American plate. It submerged an entire pine forest and farms, converting them to tidal marshes, and flooded coastal towns, killing thousands and forcing residents to abandon their homes. Earthquakes are unlikely to get much bigger because there are no fault lines on Earth large enough to generate more force. Some doubt that a magnitude ten quake could ever occur, and it would take a force 11 for true global devastation. The earthquake that struck Kamchatka Peninsula was measured at 8.8 and is the largest to have occurred worldwide since the force 9.1 Tohoku earthquake in Japan in 2011. It was powerful enough to send waves as fast as commercial jets across the Pacific and there have been at least 50 aftershocks up to a force 6.9 which will fuel the surge. Lisa McNeill, a professor of tectonics at the University of Southampton, said: 'Some fault movements don't move the seafloor much and so there is no tsunami. In the case of this earthquake, it had a very large rupture and slip, which made the earthquake large, and so a tsunami was generated. 'The waves travel across the ocean - they are small at sea but travelling fast and it is when they reach shallow water that they build in height again.' The earthquake occurred in a subduction zone where two tectonic plates meet, beneath the Kamchatka Peninsula, a huge piece of land which juts down out from the north eastern tip of Russia. Here the Pacific plate is moving in a roughly north-westerly direction about three inches a year and being forced beneath the Okhotsk plate. The area has had large earthquakes in the past, including a very large 9.1 earthquake in 1952, not far from the new earthquake. This earthquake was so powerful because it occurred at a depth of 12.8 miles, which is considered shallow, allowing it to release enormous amounts of energy into the waters above, and creating tsunami waves. Force 8 earthquakes release energy equivalent to 55 million tonnes of explosives. Tsunami waves as high as 10-13 feet were reported in Kamchatka, while four feet waves hit Hawaii, and a much smaller 12 inch surge hit a city in Hokkaido, northern Japan. Waves were expected to hit the California coast around 9am. Dr Stephen Hicks, the NERC independent research fellow and lecturer in environmental seismology at UCL, said: 'With such large earthquakes, long-period surface waves will continue travelling around the world for several days, with the planet continuing to resonate and ring like a large bell.' However it is unlikely to be as devastating as the 2011 Japanese disaster, in which 18,000 people were killed when an earthquake triggered powerful tsunami waves of up to 133ft, and instigated a major nuclear accident at the Fukushima Daiichi power station. Roughly twenty thousand earthquakes occur every year, but only a small percentage of them are classified as high magnitude. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

Yahoo

time6 days ago

  • Yahoo

Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration Potential for single intranasal or intramuscular dose could differentiate Novavax's vaccine as part of pandemic emergency preparedness efforts GAITHERSBURG, Md., July 24, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza vaccine candidate, leveraging Novavax's recombinant, protein-based nanoparticle technology and Matrix-M® adjuvant, induced robust immune responses by either single or two-dose intranasal (IN) or intramuscular (IM) administration in nonhuman primates. Results were published in Nature Communications. "These preclinical results underscore the promise and potential of our pandemic influenza program as well as the strength of our technology platform and our ability to deliver against our corporate growth strategy," said Ruxandra Draghia-Akli, MD, PhD, Executive Vice President and Head of Research and Development, Novavax. "Our R&D pipeline focuses on delivering assets ready for partnership and prioritizing areas of unmet medical need, including vaccines for avian pandemic influenza, where we see clear potential advantages for our technology compared with other vaccines that are licensed or in development." Results showed that a single dose administered by either IN or IM routes induced neutralizing antibody responses (IN: 1:54; IM: 1:1,160), at or above the 1:40 titer generally considered to be a protective antibody response. The data showed even higher levels of immunity after two doses. These data suggest that even a single IN dose has the potential to provide protective immunity in individuals previously exposed to seasonal influenza either by vaccination or infection. Further, data showed Novavax's H5N1 vaccine candidate elicited broad antibody responses, suggesting the potential to protect against forward-drift variants from currently circulating strains of the H5N1 virus. H5N1, a highly pathogenic and dynamic avian pandemic influenza virus, is of concern due to its potential to mutate into a strain adapted for sustained human-to-human transmission. To date, there have been 70 confirmed total reported human cases in the U.S., and one death associated with H5N1 avian pandemic influenza infection.1 As of July 2025, no reported cases in the U.S. have been proven to result from human-to-human transmission. As part of its corporate growth strategy, Novavax is making targeted investments in early-stage development programs to create value. Novavax intends to pursue funding, partnership and licensing opportunities for its H5N1 vaccine candidate. About Novavax Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. The Company's growth strategy seeks to optimize its existing partnerships and expand access to its proven technology platform via research and development (R&D) innovation, organic portfolio expansion in infectious disease and beyond, and forging new partnerships and collaborations with other companies. Please visit and LinkedIn for more information. Forward-Looking Statements Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, and the potential for a single intranasal or intramuscular dose differentiating Novavax's H5N1 vaccine, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges pursuing additional partnership opportunities; challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification, assay validation and stability testing, necessary to satisfy applicable regulatory authorities; challenges or delays in conducting clinical trials or studies for its product candidates; challenges or delays in obtaining regulatory authorization for its product candidates, including for future COVID-19 variant strain changes, its CIC vaccine candidate, its stand-alone influenza vaccine candidate or other product candidates; manufacturing, distribution or export delays or challenges; Novavax's substantial dependence on Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for co-formulation and filling Novavax's COVID-19 vaccine and the impact of any delays or disruptions in their operations; difficulty obtaining scarce raw materials and supplies including for its proprietary adjuvant; resource constraints, including human capital and manufacturing capacity; constraints on Novavax's ability to pursue planned regulatory pathways, alone or with partners; challenges in implementing its global restructuring and cost reduction plan; challenges in obtaining commercial adoption and market acceptance of its updated COVID-19 vaccine or any COVID-19 variant strain containing formulation, or for its CIC vaccine candidate and stand-alone influenza vaccine candidate or other product candidates; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities, including requirements to deliver doses that may require Novavax to refund portions of upfront and other payments previously received or result in reduced future payments pursuant to such agreements and challenges in amending or terminating such agreements; challenges related to the seasonality of vaccinations against COVID-19; challenges related to the demand for vaccinations against COVID-19 or influenza; challenges in identifying and successfully pursuing innovation expansion opportunities; Novavax's expectations as to expenses and cash needs may prove not to be correct for reasons such as changes in plans or actual events being different than its assumptions; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at and for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Contacts: Investors Luis Sanay, CFA 240-268-2022 ir@ Media Giovanna Chandler (844) 264-8571 media@ References U.S. Centers for Disease Control and Prevention. H5 Bird Flu: Current Situation. 2025. Available at: View original content to download multimedia: SOURCE Novavax, Inc.

Microbix Exhibiting & Presenting at ADLM
Microbix Exhibiting & Presenting at ADLM

Hamilton Spectator

time6 days ago

  • Hamilton Spectator

Microbix Exhibiting & Presenting at ADLM

MISSISSAUGA, Ontario, July 24, 2025 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be attending, exhibiting, and presenting at the Association for Diagnostic & Laboratory Medicine ('ADLM') conference taking place in Chicago, Illinois July 28 to 31, 2025. At ADLM, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of many infectious and other diseases. Microbix will thereby showcase its ever-growing portfolio of quality assessment products ('QAPs™') that help ensure the accuracy of antigen and molecular (i.e., 'PCR' or 'NAAT') tests and their workflows. Microbix will also be meeting with many current and prospective clients to determine how best to support their quality management system needs. Also at ADLM, Microbix will present results of a pilot External Quality Assessment (EQA) program enabled by Microbix QAPs. Its poster is titled 'Quality Control Rapid Response in Pre-Pandemic Preparedness Showcasing a Synthetic H5N1 Genetic Template.' which reviews the performance of novel QAPs for answering the critical question of whether pre-existing molecular tests for Influenza A can accurately detect the emerging H5N1 (Bird Flu) pandemic strain. A Microbix customer and collaborator, American Proficiency Institute ('API'), is presenting a related poster titled 'Evaluation of NAAT Recovery of Highly Pathogenic Avian Influenza A (H5N1) Clade 2.3.4.4b from Novel Proficiency Samples.' After each poster is presented at ADLM, they will be made available at . The two posters detail the results of work first announced on January 13, 2025, whereby Microbix and API disclosed the creation of QAPs and a pilot proficiency testing program for evaluating the performance of Flu tests in detecting H5N1. As widely reported in the media, H5N1 Flu is a novel variant for which the human population does not have established immunity. Accordingly, H5N1 Flu has pandemic potential, with it having thus far caused severe disease or death in approximately 50% of those persons infected. Microbix gratefully acknowledges the vital role of API in helping to conduct this societally important work. Amer Alagic, Microbix's Director of R&D and lead author of its poster commented, 'Working alongside API, our team is privileged to help answer vital questions concerning the accuracy and usefulness of currently available Flu tests for detecting H5N1. Microbix's novel H5N1 QAPs were created by our team to ensure full genetic coverage of a potential pandemic strain and were made safely under Microbix IP and with cutting-edge synthetic biology techniques. H5N1 QAPs are fully-characterized, accurately-quantified, and are available in liquid and FLOQSwab formats to support both lab-based and point-of-care assays. These Microbix capabilities can be rapidly deployed in response to any emerging pandemic.' Purchase enquiries for these or other Microbix QAPs can be e-mailed to . About Microbix Biosystems Inc. Microbix Biosystems Inc. creates proprietary biological products for human health, with over 120 skilled employees and revenues targeting C$ 2.0 million or more per month. It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency-testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR-compliant CE marked products. Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (e.g., its DxTM™ for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada. Forward-Looking Information This news release includes 'forward-looking information,' as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of API, the pilot proficiency testing program, the H5N1 QAPs, or their relevance, Microbix's or others' products or services, business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its presentations, regulatory compliance and approvals, access and sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity or timeliness of delivery), currency exchange rates, maintaining adequate working capital or raising new capital on acceptable terms or at all, and other similar statements about anticipated future events, conditions or results that are not historical facts. These statements reflect management's current estimates, beliefs, intentions, and expectations; they are not guarantees of future performance. Microbix cautions that all forward-looking information is inherently uncertain and actual performance may be affected by many material factors, some of which are beyond its control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions, and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent Microbix's judgement as of the date of this new release, and it is under no obligation to update or alter any forward-looking information. Please visit or for recent Microbix news and filings. For further information, please contact Microbix at: Copyright © 2025 Microbix Biosystems Inc. Microbix®, DxTM™, Kinlytic®, and QAPs™ are trademarks of Microbix Biosystems Inc. FLOQ® and FLOQSwab® are trademarks of Copan Italia S.p.A. Other companies' names and products are protected by their respective trademarks.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store